MSD Animal Health Presents New Data Highlighting Commitment to Swine Innovation at the 27th International Pig Veterinary Society Congress and 15th European Symposium of Porcine Health Management

Rahway, N.J., June 4, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the presentation of more than 30 studies at the 27th International Pig Veterinary Society Congress (IVPS) and 15th European Symposium of Porcine Health Management (ESPHM), highlighting new research across the company’s broad swine portfolio and initiatives. The meeting will take place June 4-7, 2024 in Leipzig, Germany.

MSD Animal Health will present data that emphasize both the economic and environmental sustainability of the industry, using IDAL, a needle-free intradermal vaccination system, and Lawsonia intracellularis vaccination as reference points. Additionally, studies will address the control of highly virulent PRRSv strains, and innovative alternatives for the detection and monitoring of enteric and respiratory pathogens, as well as for reproductive management.

“As a company committed to the overall well-being of pigs and the long-term sustainability of the swine industry, MSD Animal Health is pleased to share insights from our range of cutting-edge vaccines, health management solutions, and value-added services,” affirmed Rika Jolie, DVM, Ph.D., MBA, Head of Global Swine, MSD Animal Health. “This latest research reinforces our unwavering dedication to advancing the field of Animal Health and showcases how our state-of-the-art scientific breakthroughs, products, and solutions can substantially benefit both swine and farmers.”

Key data to be presented at IVPS/ESPHM 2024 include:

  • A Cost minimization analysis of intradermal and intramuscular administration of vaccines in Brazil

Intradermal (ID) administration of vaccines is an alternative to traditional routes of administration, such as intramuscular (IM) and oral that may result in lower costs for producers. Fewer resources were required under the ID scenario due to the smaller doses, vial sizes and packaging, and the elimination of needles and syringes. The total cost savings associated with the ID scenario compared to IM was $65,776 USD annually or $0.06 USD per pig marketed.

  • Experimental assessment of the efficacy of an MLV PRRS vaccine against challenge with highly virulent PRRSV-1 strain Rosalia

The aim of the study was to assess the efficacy of a modified live (MLV) porcine respiratory and reproductive syndrome (PRRS) vaccine against the challenge with one of those highly virulent isolates. Vaccination with a MLV vaccine administered intradermally resulted in significant clinical, pathological, virological and zootechnical protection against the challenge with highly virulent Rosalia, which is a severe challenge for the Spanish swine industry and a concern for most of European markets.

  • Effect of improved feed conversion ratio by Lawsonia intracellularis vaccination on the carbon footprint

A model calculation demonstrated a reduction of greenhouse gas emissions associated with improved feed efficiency in pigs vaccinated against Lawsonia intracellularis. This suggests that improved feed efficiency contributes to sustainability in pig production.

  • Effect of improved feed efficiency by Lawsonia intracellularis vaccination on Nitrogen emission in fattening pigs

Nitrogen emission (N-emission) from pig farms can be limited by reducing crude protein content in feed and increasing feed efficiency by Lawsonia intracellularis vaccination. This suggests that both are favorable and suitable tools to reduce N-emission, making pig production more sustainable.

  • Effect of amoxicillin, ceftiofur, doxycycline, tiamulin and tulathromycin on the antibody response of piglets vaccinated against Lawsonia intracellularis.

The use of some antibiotics during the development of the adaptive humoral immune response can affect the serological potency of immunogenic vaccines. This negative effect may be especially important in vaccines whose antibody response needs to reach its maximum level in the early stages of nursery phase (e.g., vaccines against Glaesserella parasuis and Streptococcus suis).

MSD Animal Health scientific publications will be available on after the congress. Please visit booth #B10 for more information.

About MSD Animal Health

At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of MSD. Through its commitment to The Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit and connect with us on LinkedIn and X (formerly Twitter).

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could

cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (